BIO-TECHNE Corp (TECH) stock analysis

P/E above its 5-year median

Bio-Techne's P/E of 66.8 is above its own 5-year median of 62.7.

P/E above the industry

Bio-Techne's P/E of 66.8 is above the Drugs median of 25.0.

EV/EBITDA below its 5-year median

Bio-Techne's EV/EBITDA of 33.4 is below its 5-year median of 33.9.

P/B above the industry

Bio-Techne's price-to-book of 5.28 is above the Drugs median of 2.20.

Trading above fair value

The share price of $72.84 is above our fair value estimate of $51.82.

Margin of safety under 20%

The price is 40.6% above fair value, so there is no margin of safety.

Revenue growing under 10% a year

Revenue grew 2.2% a year over the last three fiscal years, short of the 10% we look for.

EPS growing under 10% a year

Diluted EPS grew -13.0% a year over the last three fiscal years.

Earnings acceleration

Needs positive net income now, a year ago and five years ago.

Growing slower than the industry

Revenue grew 0.9% over the last twelve months; the Drugs median is 7.6%.

Company guidance

No outlook found in earnings releases from the last twelve months.

Gross margin improving

Gross margin was 65.8% over the last twelve months, against 65.4% a year earlier.

Return on equity

Needs positive equity and five years of results.

Return on capital under 10%

Return on invested capital was 8.8%, below the 10% that usually covers the cost of capital.

Return on equity against the industry

Needs positive equity.

Earnings over 5 years

Needs positive net income five years ago and in the latest year.

Net margin against its history

Needs five years of revenue and net income.

Net margin against the industry

Needs revenue and net income.

Low debt

Debt is 9.2% of shareholders' equity, under the 40% we consider low.

Debt falling against equity

Debt to equity fell from 21.8% five years ago to 9.2%.

Debt covered by cash flow

Operating cash flow over the last twelve months equals 169% of total debt.

Interest well covered

Operating income covers interest expense 27.2 times.

Short-term assets cover short-term debts

Current assets are 2.28 times current liabilities.

Low bankruptcy risk

The Altman Z-score is 16.16; above 3 is the safe zone and below 1.8 the distress zone.

Pays a dividend

Bio-Techne paid dividends worth 0.5% of the share price over the last twelve months.

Yield below Treasuries

The 0.5% yield is below the 4.6% on a 1-year Treasury.

Yield below the top quarter

The top quarter of US dividend payers yield 3.9% or more; Bio-Techne yields 0.5%.

Dividend not cut

The dividend per share has not fallen by more than 10% in any of the last 10 fiscal years.

Earnings cover

Needs dividends paid and net income.

Covered by free cash flow

Dividends take 16.2% of free cash flow.